RECEIVED CENTRAL FAX CENTER

FEB 0 5 2007

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (original)

An axon growth stimulation kit comprising
a first container means for containing a flowable carrier component or two or
more separate components capable once intermingled of forming a flowable
carrier component, said flowable carrier components each being capable of
forming a therapeutically acceptable matrix in vivo at a nerve lesion site
and
a second container means for containing a therapeutically active agent for
facilitating axon growth at the lesion site
wherein said therapeutically active agent is releasable from said in vivo
matrix into the adjacent external environment.

Claim 2. (original) An axon growth stimulation kit as defined in claim 1 comprising means for dispersing the therapeutically active agent in said flowable carrier component so as to form a flowable axon growth stimulation composition and

means for deliverying the flowable axon growth stimulation composition to the lesion site.

Claim 3. (original) An axon growth stimulation kit as defined in claim 1 wherein said therapeutically acceptable matrix is a collagen matrix.

Claim 4. (withdrawn) An axon growth stimulation kit as defined in claim 1 wherein said therapeutically acceptable matrix is a fibrin matrix.

Claim 5. (original) A biocompatible composition comprising: (i) at least one supplement selected from the group consisting of therapeutically active agents for facilitating axon growth; and (ii) a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site; wherein said supplement is releasable from said matrix into the adjacent external environment.

Claim 6. (original) A biocompatible composition as defined in claim 5 wherein said therapeutically acceptable matrix is a collagen matrix.

Claim 7 (withdrawn) A biocompatible composition as defined in claim 5 wherein said therapeutically acceptable matrix is a fibrin matrix.

Claims 8 (withdrawn) A method for the preparation of a flowable biocompatible composition comprising admixing (i) at least one supplement selected from the group consisting of therapeutically active agents for facilitating axon growth and (ii) a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site; wherein said supplement is releasable from said matrix into the adjacent external environment.

Claim 9 (withdrawn) A method as defined in claim 8 wherein said therapeutically acceptable matrix is a collagen matrix.

Claim 10 (withdrawn) A method as defined in claim 8 wherein said therapeutically acceptable matrix is a fibrin matrix.